Bastian Schilling
Experienced in Metastatic Brain Tumor

Bastian Schilling

Josef Schneider Str. 2, 
Wuerzburg, BY, DE 
Experienced in Metastatic Brain Tumor
Josef Schneider Str. 2, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Bastian Schilling practices in Wuerzburg, Germany. Mr. Schilling is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Melanoma, Nevoid Basal Cell Carcinoma Syndrome, Uveal Melanoma, and Merkel Cell Carcinoma.

His clinical research consists of co-authoring 195 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Josef Schneider Str. 2, Wuerzburg, BY 97080, Germany
Other Locations
Oberdürrbacher Str. 6, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
View 3 Less Clinical Trials

195 Total Publications

Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis.
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis.
Journal: Journal for immunotherapy of cancer
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schilling's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile